Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (27)

2024

  1. Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathy

    Frontiers in Cell and Developmental Biology, Vol. 12

2023

  1. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811

  2. Neuroimaging in infants with congenital cytomegalovirus infection and its correlation with outcome: emphasis on white matter abnormalities

    Archives of Disease in Childhood: Fetal and Neonatal Edition, Vol. 109, Núm. 2, pp. 151-158

  3. Selection of the best of 2022 in arrhythmias and cardiac pacing

    REC: CardioClinics, Vol. 58, pp. S35-S41

  4. Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads

    Journal of Interventional Cardiac Electrophysiology, Vol. 66, Núm. 7, pp. 1589-1600

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  2. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update)

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 14, Núm. 1, pp. 5-12

  3. Treatable traits in the NOVELTY study

    Respirology, Vol. 27, Núm. 11, pp. 929-940

2021

  1. Environmental exposure during pregnancy: Influence on prenatal development and early life: A comprehensive review

    Fetal Diagnosis and Therapy, Vol. 48, Núm. 4, pp. 245-257

  2. Multilingual Naming

    Intraoperative Mapping of Cognitive Networks: Which Tasks for Which Locations (Springer International Publishing), pp. 219-231

  3. Recomendaciones de la SEIOMM en la prevención y tratamiento del déficit de vitamina D

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 13, Núm. 2, pp. 84-97

  4. SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients

    Rheumatology (United Kingdom), Vol. 60, Núm. 6, pp. 2946-2957

2020

  1. Holistic approach of the care of the infant with hypoxic-ischaemic encephalopathy in Spain

    Anales de Pediatria, Vol. 92, Núm. 5, pp. 286-296

2019

  1. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 5

  2. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

    Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106

  3. The Big Data Sjögren consortium: A project for a new data science era

    Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23

2018

  1. Dalbavancin in the treatment of different gram-positive infections: a real-life experience

    International Journal of Antimicrobial Agents, Vol. 51, Núm. 4, pp. 571-577

  2. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

2017

  1. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

2015

  1. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

    Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457